All articles by GlobalData Healthcare

GlobalData Healthcare

What does Biden’s directive on foreign biotech investments mean for manufacturers?

Regulation of biotech and manufacturing deals in the US could prompt foreign companies to seek alternative targets elsewhere.

A game of two halves for Roche’s recently approved wet AMD assets

Roche has received US FDA approval of two wAMD therapies, but one was recently recalled due to a manufacturing defect.

Immediate steps are needed to reduce the ‘twindemic’ impact in Europe and the US

Governmental bodies should use Australia as a case study and make decisions now to keep healthcare systems from being overwhelmed.

Myovant Sciences rejects $2.5bn takeover bid from Sumitomo Pharma

The offer comes after Myovant and Pfizer received FDA expanded approval of Myfembree for moderate to severe endometriosis pain.

Novo Nordisk submitting once-weekly insulin to FDA following Phase III success

Insulin icodec has achieved significant results in all of its clinical trials.

High risk, high reward – the future of CAR-T therapy in CLL

There is potential for CAR-T therapy products to penetrate the CLL market due to unmet needs among end-stage refractory patients.

European Commission’s approval of Mounjaro provides hope within obesity space

Mounjaro has overwhelming potential to be favoured among many patients and clinicians alike if it is approved for obesity.

bluebird bio wins back-to-back landmark FDA approvals for first-in-class gene therapies

The approvals represent crucial milestones for bluebird bio, the gene therapy field, and patients with rare genetic diseases.

Sandoz spin-off continues Novartis’ focus on innovation; $22bn purchase rumoured

Both Sandoz and Novartis are internationally renowned pharma companies, with a total of 34 production facilities worldwide.

Drug developers look at innovative mechanisms to tackle dry eye syndrome

As late-stage therapies for DES progress through clinical development, physicians and patients grow increasingly excited.